Skip to main content Accessibility help
×
Home

Rediscovering an old friend: a role for insulin growth factor-2 in reducing neurodegeneration, decreasing amyloid beta, and improving memory

  • Ruth O’Hara (a1) and Joachim Hallmayer (a1)

Abstract

  • An abstract is not available for this content so a preview has been provided below. Please use the Get access link above for information on how to access this content.

Copyright

References

Hide All
Åberg, D. et al. (2015). Increased cerebrospinal fluid level of insulin-like growth factor-II in male patients with Alzheimer’s disease. Journal of Alzheimer’s Disease, 48, 637646.
Allegri, R. F. et al. (2019). A biological classification for Alzheimer’s disease—Amyloid, Tau and Neurodegeneration (A/T/N): results from the Argentine-Alzheimer’s Disease Neuroimaging Initiative. International Psychogeriatrics. doi: 10.1017/S1041610219000085.
Chami, B., Steel, A. J., De La Monte, S. M. and Sutherland, G. T. (2016). The rise and fall of insulin signaling in Alzheimer’s disease. Metabolic Brain Disease, 31, 497515.
Chen, D. Y. et al. (2011). A critical role for IGF-II in memory consolidation and enhancement. Nature, 469, 491497.
Duron, E. et al. (2012). Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer’s disease. The Journal of Clinical Endocrinology & Metabolism, 97, 46734681.
Hanyu, H. (2019). Diabetes-related dementia. Advances in Experimental Medicine and Biology, 1128, 147160.
Hawkes, C., Jhamandas, J. H., Harris, K. H., Fu, W., MacDonald, R. G. and Kar, S. (2006). Single transmembrane domain insulin-like growth factor-II/mannose-6-phosphate receptor regulates central cholinergic function by activating a G-protein-sensitive, protein kinase C-dependent pathway. The Journal of Neuroscience, 26, 585596.
Kita, Y., Ago, Y., Takano, E., Fukada, A., Takuma, K. and Matsuda, T. (2013). Galantamine increases hippocampal insulin-like growth factor 2 expression via 7 nicotinic acetylcholine receptors in mice. Psychopharmacology, 225, 543551.
Knusel, B., Michel, P. P., Schwaber, J. S. and Hefti, F. (1990). Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. The Journal of Neuroscience, 10, 558570.
Martin-Montañez, E. et al. (2014). Involvement of IGF-II receptors in the antioxidant and neuroprotective effects of IGF-II on adult cortical neuronal cultures. Biochimica et Biophysica Acta, 1842, 10411051.
Mellott, T. J., Pender, S. M., Burke, R. M., Langley, E. A. and Blusztajn, J. K. (2014). IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer’s disease model mice. PLoS One, 9, e9428.
Mirandez, R. M., Aprahamian, I., Talib, L. L., Forlenza, O. V. and Radanovic, M. (2017). Multiple category verbal fluency in mild cognitive impairment and correlation with CSF biomarkers for Alzheimer’s disease. International Psychogeriatrics, 29, 949958.
Pardo, M. et al. (2018). Insulin growth factor 2 (IGF2) as an emergent target in psychiatric and neurological disorders. Review. Neuroscience Review, pii: S0168-0102(18)30435-8.
Pascual-Lucas, M. et al. (2014). Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Molecular Medicine, 6, 12461262.
Shahmoradi, A., Radyushkin, K. and Rossner, M. J. (2015). Enhanced memory consolidation in mice lacking the circadian modulators Sharp1 and -2 caused by elevated IGF2 signaling in the cortex. Proceedings of the National Academy of Sciences of the United States of America, 112, E3582E3589.
Steen, E. et al. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? Journal of Alzheimer’s Disease, 7, 6380.
Stern, S. A., Chen, D. Y. and Alberini, C. M. (2014). The effect of insulin and insulin-like growth factors on hippocampus- and amygdala-dependent long-term memory formation. Learning & Memory, 21, 556563.
Wennberg, A. M. et al. (2014). Diabetes and cognitive outcomes in a nationally representative sample: the National Health and Aging Trends Study. International Psychogeriatrics, 26, 17291735.
Xia, L. et al. (2019). Genome-wide RNA sequencing analysis reveals that IGF-2 attenuates memory decline, oxidative stress and amyloid plaques in Alzheimer’s disease mouse model (AD) by activating the PI3K/AKT/CREB signaling pathway. International Psychogeriatrics, 31, 947959. doi: 10.1017/S1041610219000383.

Rediscovering an old friend: a role for insulin growth factor-2 in reducing neurodegeneration, decreasing amyloid beta, and improving memory

  • Ruth O’Hara (a1) and Joachim Hallmayer (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed